AAX Biotech are a research-driven company specialising in next-generation antibody therapeutics. Their proprietary technologies Seqitope® and Opti-mAb®—address key challenges in antibody development. Seqitope® enables high-resolution, high-throughput epitope mapping, while Opti-mAb® stabilizes scFv antibodies, improving their manufacturability and efficacy in applications like bispecific antibodies and CAR-T therapies.